This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cox, D. Articles by Fitzgerald, D. J. Search for Related Content PubMed PubMed Citation Articles by Cox, D. Articles by Fitzgerald, D. J.

Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes

Dermot Cox, BSc, PhD^*, Richard Smith, BSc, PhD^*, Martin Quinn, MD^*, Pierre Theroux, MD, Peter Crean, MD and Desmond J. Fitzgerald, MD^*

^* Centre for Cardiovascular Science, Royal College of Surgeons in Ireland, Dublin, Ireland
Montreal Heart Institute, Montreal, Quebec, Canada
Department of Cardiology, St. James Hospital, Dublin, Ireland

View larger version (22K): [in a new window]   Figure 1 Percent platelet aggregation (± SEM) to ADP (20 µmol/liter) and TRAP (5 µmol/liter) in patients on placebo (n = 24–31) (diamond); orbofiban 30 mg bid (n = 17–29) (solid square); 40 mg bid (n = 21–29) (diamond); 50 mg qd (n = 16–29) (open square); and 50 mg bid (n = 18–31) (open circle).

View larger version (17K): [in a new window]   Figure 2 The effect of placebo (solid square) and 50 mg bid orbofiban (solid triangle) on receptor occupancy measured as the ratio of mAb2 to mAb1 binding (n = 4–6).

View larger version (10K): [in a new window]   Figure 3 The effect of orbofiban and abciximab+orbofiban on 4F8-induced thromboxane formation.